Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitiveBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8464 (Published 12 December 2012) Cite this as: BMJ 2012;345:e8464
- Bob Roehr
- 1Washington, DC
The US Supreme Court has agreed to review the legality of so called pay for delay agreements where the owner of a branded drug pays another drug company not to bring a generic version of that drug to market for an agreed time period.
Such agreements are one tool used by patent holders to effectively extend the period of exclusivity of their drug on the market. They allow the patent holders to charge higher prices than if a generic equivalent were also available. Legal challenges to the practice have been going through the courts for a number of years, with varying outcomes.
Some generic drug manufacturers have challenged a patent, and often the company holding …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial